Personalized PRRT of Neuroendocrine Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

April 12, 2016

Primary Completion Date

April 12, 2025

Study Completion Date

April 12, 2029

Conditions
Neuroendocrine TumorsCarcinoid TumorCarcinoma, Neuroendocrine
Interventions
DRUG

177Lu-Octreotate

"* The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."

Trial Locations (1)

G1R 2J6

CHU de Québec - Université Laval, Québec

All Listed Sponsors
lead

CHU de Quebec-Universite Laval

OTHER